Prevention and management of acute reactions to intravenous iron in surgical patients

Blood Transfusion

Volumn 17, Issue 2, 2019, Pages 137-145

  Gómez Ramírez, Susana ^a,b   Shander, Aryeh ^c,d   Spahn, Donat R ^e   Auerbach, Michael ^f   Liumbruno, Giancarlo M ^g   Vaglio, Stefania ^g   Muñoz, Manuel ^a  

^a UNIVERSITY OF MÁLAGA   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c ENGLEWOOD HOSPITAL AND MEDICAL CENTER   (United States)

^d TeamHealth Research Institute   (United States)

^e UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^f GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Anaphylaxis; Hypotension; Infusion reaction; Intravenous iron; Management

Indexed keywords

IRON;

ACUTE DISEASE; ALLERGIC REACTION; ANAPHYLAXIS; HUMAN; HYPOTENSION; IRON DEFICIENCY ANEMIA; REVIEW; RISK; SUPPLEMENTATION; SURGICAL PATIENT; CHEMICALLY INDUCED; DISEASE MANAGEMENT; INTRAVENOUS DRUG ADMINISTRATION; RISK FACTOR;

ADMINISTRATION, INTRAVENOUS; ANAPHYLAXIS; ANEMIA, IRON-DEFICIENCY; DISEASE MANAGEMENT; HUMANS; HYPOTENSION; IRON; RISK FACTORS;

EID: 85064341359     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2018.0156-18     Document Type: Review

References (66)

1. Muñoz M, Gómez-Ramírez S, Kozek-Langeneker S, et al. 'Fit to fly': overcoming barriers to preoperative haemoglobin optimization in surgical patients. Br J Anaesth 2015; 115: 15-24.
2. Muñoz M, Gómez-Ramírez S, Campos A, et al. Preoperative anaemia: prevalence, consequences and approaches to management. Blood Transfus 2015; 13: 370.
3. Ranucci M, Baryshnikova E, Castelvecchio S, Pelissero G; Surgical and Clinical Outcome Research (SCORE) Group. Major bleeding, transfusions, and anemia: the deadly triad of cardiac surgery. Ann Thorac Surg 2013; 96: 478-85.
4. Muñoz M, Laso-Morales MJ, Gómez-Ramírez S, et al. Pre-operative haemoglobin levels and iron status in a large multicentre cohort of patients undergoing major elective surgery. Anaesthesia 2017; 72: 826-34.
5. Muñoz M, Acheson AG, Auerbach M, et al. International consensus statement on the peri-operative management of anaemia and iron deficiency. Anaesthesia 2017; 72: 233-12.
6. Shander A, Van Aken H, Colomina MJ, et al. Patient blood management in Europe.Br J Anaesth 2012; 109: 55-68.
7. Vaglio S, Prisco D, Biancofiore G, et al. Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfus 2016; 14: 23-65.
8. Vaglio S, Gentili S, Marano G, et al. The Italian Regulatory Guidelines for the implementation of Patient Blood Management. Blood Transfus 2017; 15: 325-8.
9. NICE guideline [NG24]. Blood transfusion. Available at: https://www.nice.org.uk/guidance/ng24/chapter/Recommendations#alternatives-to-blood-transfusionfor- patients-having-surgery-2. Accessed on 27/06/2018.
10. Muñoz M, Gómez-Ramírez S, Bhandari S. The safety of available treatment options for iron-deficiency anemia. Expert Opin Drug Saf 2018; 17: 149-59.
11. Muñoz M, Gómez-Ramírez S, Besser M, et al. Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus 2017; 15: 422-37.
12. Muñoz M, Acheson AG, Bisbe E, et al. An international consensus statement on the management of postoperative anaemia after major surgical procedures. Anaesthesia 2018; 73: 1418-31.
13. European Medicines Agency. EMA/579491/2013. New recommendations to manage risk of allergic reactions with intravenous iron containing medicines. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/IV-iron-31/WC500151308.pdf. Accessed on 18/07/2018.
14. Goodnough LT, Maniatis A, Earnshaw P, et al. Detection, evaluation, and management of preoperative anaemia in the elective orthopaedic surgical patient: NATA guidelines. Br J Anaesth 2011; 106: 13-22.
15. Leal-Noval SR, Muñoz M, Asuero M, et al. Spanish Expert Panel on Alternatives to Allogeneic Blood Transfusion. Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document". Blood Transfus 2013; 11: 585-610.
16. SABM. Anemia prevention and management program implementation guide, 2015. Available at: https://www.sabm.org/sites/default/files/anemia-prevention- management-program-implementation-guide.pdf. Accessed on 11/07/2018.
17. American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology 2015; 122: 241-75.
18. Kotzé A, Harris A, Baker C, et al. British Committee for Standards in Haematology Guidelines on the Identification and Management of Pre- Operative Anaemia. Br J Haematol 2015; 171: 322-31.
19. Kozek-Langenecker SA, Afshari A, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. First update 2016. Eur J Anaesthesiol 2017; 43: 332-95.
20. Jahn MR, Andreasen HB, Fütterer S, et al. A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm 2011; 78: 480-91.
21. Ferrlecit® summary of product characteristics. Available at: http://www.products.sanofi-aventis.us/ferrlecit/ferrlecit. pdf. Accessed on: 18/07/2018.
22. Venofer summary of product characteristics. Available at: http://www.luitpold.com/documents/22.pdf. Accessed on: 18/07/2018.
23. Cosmofer® summary of product characteristics. Available at: http://www.cosmofer.com/product/cosmofer-spc/cosmofer-spc.aspx. Accessed on: 18/07/2018.
24. Ferinject® summary of product characteristics. Available at: http://www.ferinject.co.uk/smpc/. Accessed on: 18/07/2018.
25. Monofer® summary of product characteristics. Available at: http://www.monofer.com/spc.aspx. Accessed on: 18/07/2018.
26. FeraHeme® summary of product characteristics. Available at: http://www.feraheme.com/pdfs/Feraheme-Prescribing- Information.pdf. Accessed on: 18/07/2018.
27. Auerbach M, Pappadakis JA, Bahrain H, et al. Safety and efficacy of rapidly administered (one hour) one gram of low molecular weight iron dextran (INFeD) for the treatment of iron deficient anemia. Am J Hematol 2011; 86: 860-2.
28. Auerbach M, Macdougall I. The available intravenous iron formulations: History, efficacy, and toxicology. Hemodial Int. 2017; 21 (Suppl 1): S83-S89.
29. Auerbach M, Muñoz M, Macdougall IC. Intravenous iron: out of sight, out of mind. Lancet Haematol. 2018; 5: e10-e12
30. Chertow GM, Mason PD, Vaage-Nilsen O, Ahlmen J. Update on adverse drug events associated with parenteral iron. Nephrol Dial Transplant. 2006; 21: 378-382.
31. Bolton-Maggs PH, Cohen H. Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol. 2013; 163: 303-14.
32. Szebeni J, Fishbane S, Hedenus M, et al. Hypersensitivity to intravenous iron: classification, terminology, mechanisms and management. Br J Pharmacol. 2015; 172: 5025-36.
33. Auerbach M, Ballard H, Glaspy J. Clinical update: intravenous iron for anaemia. Lancet 2007; 369: 1502-4.
34. Macdougall IC, Bircher AJ, Eckardt KU, et al. Conference Participants. Iron management in chronic kidney disease: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2016; 89:28-39.
35. Avni T, Bieber A, Grossman A, et al. The safety of intravenous iron preparations: Systematic review and meta-analysis. Mayo Clinic Proceedings 2015; 90: 12-23.
36. Auerbach M, Adamson J, Bircher A, et al. On the safety of intravenous iron, evidence trumps conjecture. Haematologica 2015; 100: e214-e215.
37. Rampton D, Folkersen J, Fishbane S, et al. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica 2014; 99:1671-6.
38. Muñoz M, Martín-Montañez E. Ferric carboxymaltose for the treatment of iron-deficiency anemia. Expert Opin Pharmacother 2012; 13: 907-21.
39. Kalra PA, Bhandari S, Saxena S, et al. A randomized trial of iron isomaltoside 1000 versus oral iron in non-dialysisdependent chronic kidney disease patients with anaemia. Nephrol Dial Transplant 2016; 31: 646-55.
40. Derman R, Roman E, Modiano MR, et al. A randomized trial of iron isomaltoside versus iron sucrose in patients with iron deficiency anemia. Am J Hematol. 2017; 92: 286-91.
41. Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer®) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis. 2016; 9: 53-64.
42. Rosner MH, Auerbach M. Ferumoxytol for the treatment of iron deficiency. Expert Rev Hematol 2011; 4: 399-406.
43. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM. Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 2003; 40: 643-72.
44. Vadas P, Perelman B, Liss G. Platelet-activating factor, histamine, and tryptase levels inhuman anaphylaxis. J Allergy Clin Immunol 2013; 131: 144-9.
45. Burns DL, Pomposelli JJ. Toxicity of parenteral iron dextran therapy. Kidney Int Suppl 1999; 69: S119-S124.
46. Novey HS, Pahl M, Haydik I, et al. Immunologic studies of anaphylaxis to iron dextran in patients on renal dialysis. Ann Allergy 1994; 72: 224-8.
47. Macdougall IC, Vernon K. Complement activation-related pseudo-allergy: a fresh look at hypersensitivity reactions to intravenous iron. Am J Nephrol 2017; 45: 60-2.
48. Hempel JC, Poppelaars F, Gaya da Costa M, et al. Distinct in vitro complement activation by various intravenous iron preparations. Am J Nephrol 2017; 45: 49-59.
49. Akhuemonkhan E, Parian A, Carson KA, Hutfless S. Adverse reactions after intravenous iron infusion among inflammatory bowel disease patients in the United States, 2010-2014. Inflamm Bowel Dis 2018; 24: 1801-7.
50. Wysowski DK, Swartz L, Borders-Hemphill BV, et al. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010; 85: 650-4.
51. Auerbach M, Chaudhry M, Goldman H, Ballard H. Value of methylprednisolone in prevention of the arthralgia-myalgia syndrome associated with the total dose infusion of iron dextran: a double blind randomized trial. J Lab Clin Med 1998; 131: 257-60.
52. Barton JC, Barton EH, Bertoli LF, et al. Intravenous iron dextran therapy in patients with iron deficiency and normal renal function who failed to respond to or did not tolerate oral iron supplementation. Am J Med 2000; 109: 27-32.
53. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol 2016; 91: 31-8.
54. Charytan C, Schwenk MH, Al-Saloum MM, Spinowitz BS. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products. Nephron Clin Pract. 2004; 96: c63-c66
55. Schaefer P. Acute and chronic urticaria: Evaluation and treatment. Am Fam Physician 2017; 95: 717-24.
56. Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014; 133: 1270-7.
57. Zuberbier T, Aberer W, Asero R, et al. European Academy of Allergy and Clinical Immunology; Global Allergy and Asthma European Network; European Dermatology Forum; World Allergy Organization. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69: 868-87.
58. Fedorowicz Z, van Zuuren EJ, Hu N. Histamine H2- receptor antagonists for urticaria. Cochrane Database of Systematic Reviews 2012; 3: CD008596.
59. Pollack CV Jr, Romano TJ. Outpatient management of acute urticaria: the role of prednisone. Ann Emerg Med. 1995; 26: 547-51.
60. American Academy of Allergy, Asthma, and Immunology. Choosing Wisely Campaign. Available at: http://www. choosingwisely.org/wp- content/uploads/2015/02/AAAAIChoosing- Wisely-List.pdf. Accessed on 25/07/2018.
61. Zilberstein J, McCurdy MT, Winters ME. Anaphylaxis. J Emerg Med 2014; 47: 182-7.
62. Choo KJ, Simons E, Sheikh A. Glucocorticoids for the treatment of anaphylaxis: Cochrane systematic review. Allergy 2010; 65: 1205-11.
63. LoVerde D, Iweala OI, Eginli A, Krishnaswamy G. Anaphylaxis. Chest. 2018; 153: 528-43.
64. Spahn DR, Zacharowski K. Mild anaemia indeed requires treatment. Br J Anaesth. 2016; 116: 729-30.
65. Leahy MF, Hofmann A, Towler S, et al. Improved outcomes and reduced costs associated with a health-system-wide patient blood management program: a retrospective observational study in four major adult tertiary-care hospitals. Transfusion 2017; 57: 1347-58.
66. Bircher A, Auerbach M. Hypersensitivity from intravenous iron products. Immunol Allergy Clin N Am 2014; 34: 707-23.